Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: Relevance to pulmonary lymphangioleiomyomatosis

Molecular Pharmacology

Volumn 76, Issue 4, 2009, Pages 766-777

  Goncharova, Elena A ^a   Goncharov, Dmitry A ^a   Damera, Gautam ^a   Tliba, Omar ^c   Amrani, Yassine ^d   Panettieri Jr , Reynold A ^a   Krymskaya, Vera P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RAPAMYCIN; SMALL INTERFERING RNA; STAT3 PROTEIN; TUMOR SUPPRESSOR COMPLEX 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG FIBROBLAST; LYMPHANGIOLEIOMYOMATOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY VASCULAR DISEASE; SMOOTH MUSCLE FIBER; XENOGRAFT;

CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; LUNG DISEASES; LYMPHANGIOMYOMA; PHOSPHORYLATION; PROTEIN KINASES; RESPIRATORY FUNCTION TESTS; SIROLIMUS; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 70349331249     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.109.057042     Document Type: Article

References (40)

1. Agarwal C, Tyagi A, Kaur M, and Agarwal R (2007) Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 28:1463-1470. (Pubitemid 47243538)
2. Al Zaid Siddiquee K and Turkson J (2008) STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18:254-267. (Pubitemid 351206162)
3. Bai Y, Ahmad U, Wang Y, Li JH, Choy JC, Kim RW, Kirkiles-Smith N, Maher SE, Karras JG, Bennett CF, et al. (2008) Interferon-γ induces X-linked inhibitor of apoptosis-associated factor-1 and Noxa expression and potentiates human vascular smooth muscle cell apoptosis by STAT3 activation. J Biol Chem 283:6832-6842.
4. Baybis M, Yu J, Lee A, Golden JA, Weiner H, McKhann G 2nd, Aronica E, and Crino PB (2004) mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol 56:478-487.
5. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, et al. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358:140-151.
6. Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, and Russo A (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197:157-168. (Pubitemid 37485244)
7. Dabora SL, Roberts P, Nieto A, Perez R, Jozwiak S, Franz D, Bissler J, Thiele EA, Sims K, and Kwiatkowski DJ (2002) Association between a high-expressing interferon- gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients. Am J Hum Genet 71:750-758. (Pubitemid 135750509)
8. El-Hashemite N and Kwiatkowski DJ (2005) Interferon-gamma-Jak-Stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a potential therapeutic target. Am J Respir Cell Mol Biol 33:227-230. (Pubitemid 41254289)
9. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, and Kwiatkowski DJ (2004) Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res 64:3436-3443. (Pubitemid 38657915)
10. Fang P, Hwa V, and Rosenfeld RG (2006) Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway. Exp Cell Res 312:1229-1239.
11. Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA, and Krymskaya VP (2002a) PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 283:L354-L363. (Pubitemid 34803992)
12. Goncharova EA and Krymskaya VP (2008) Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges. J Cell Biochem 103:369-382.
13. Goncharova EA, Goncharov DA, Chisolm A, Spaits MS, Lim PN, Cesarone G, Khavin I, Tliba O, Amrani Y, Panettieri RA Jr, et al. (2008) Interferon β augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation. Mol Pharmacol 73:778-788.
14. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, et al. (2002b) Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 277:30958-30967. (Pubitemid 34970798)
15. Goncharova EA, Goncharov DA, Spaits M, Noonan DJ, Talovskaya E, Eszterhas A, and Krymskaya VP (2006a) Abnormal smooth muscle cell growth in lymphangioleiomyomatosis: role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 34:561-572.
16. Goncharova EA, Lim P, Goncharov DA, Eszterhas A, Panettieri RA Jr, and Krymskaya VP (2006b) Assays for in vitro monitoring proliferation of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cells. Nat Protoc 1:2905-2908.
17. Gough DJ, Levy DE, Johnstone RW, and Clarke CJ (2008) IFNgamma signaling- does it mean JAK-STAT? Cytokine Growth Factor Rev 19:383-394.
18. Hino O, Kobayashi T, and Mitani H (2002) Prevention of hereditary carcinogenesis. Proc Jpn Acad 78:31-33.
19. Hino O, Kobayashi T, Momose S, Kikuchi Y, Adachi H, and Okimoto K (2003) Renal carcinogenesis: genotype, phenotype and dramatype. Cancer Sci 94:142-147. (Pubitemid 36575872)
20. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, and Walker C (1995) Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 146:1568-1579.
21. Kaur S, Lal L, Sassano A, Majchrzak-Kita B, Srikanth M, Baker DP, Petroulakis E, Hay N, Sonenberg N, Fish EN, et al. (2007) Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling. J Biol Chem 282:1757-1768. (Pubitemid 47076718)
22. Krymskaya VP and Goncharova EA (2009) PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 8:403-413.
23. Lee L, Sudentas P, and Dabora SL (2006) Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer 45:933-944. (Pubitemid 44360180)
24. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, et al. (2005) Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42:213-227. (Pubitemid 40171186)
25. Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L, et al. (2009) The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 28:961-972.
26. Li Y, Inoki K, and Guan KL (2004) Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity. Moll Cell Biol 24:7965-7975. (Pubitemid 39167447)
27. Messina MP, Rauktys A, Lee L, and Dabora SL (2007) Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. BMC Pharmacol 7:14. (Pubitemid 351167792)
28. Nguyen H, Ramana CV, Bayes J, and Stark GR (2001) Roles of phosphatidylinositol 3-kinase in interferon-γ-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J Biol Chem 276:33361-33368. (Pubitemid 37384543)
29. Ni CW, Hsieh HJ, Chao YJ, and Wang DL (2003) Shear flow attenuates serum-induced STAT3 activation in endothelial cells. J Biol Chem 278:19702-19708. (Pubitemid 36799155)
30. Niu G, Heller R, Catlett-Falcone R, Coppola D, Jaroszeski M, Dalton W, Jove R, and Yu H (1999) Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59:5059-5063. (Pubitemid 29503958)
31. Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5:375-386.
32. Qing Y and Stark GR (2004) Alternative activation of STAT1 and STAT3 in response to interferon-γ. J Biol Chem 279:41679-41685. (Pubitemid 39313613)
33. Riemenschneider MJ, Betensky RA, Pasedag SM, and Louis DN (2006) AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 66:5618-5622.
34. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6:729-734.
35. Sakamoto E, Hato F, Kato T, Sakamoto C, Akahori M, Hino M, and Kitagawa S (2005) Type I and type II interferons delay human neutrophil apoptosis via activation of STAT3 and up-regulation of cellular inhibitor of apoptosis 2. J Leukoc Biol 78:301-309. (Pubitemid 40979969)
36. Simon AR, Takahashi S, Severgnini M, Fanburg BL, and Cochran BH (2002) Role of the JAK-STAT pathway in PDGF-stimulated proliferation of human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 282:L1296-L1304. (Pubitemid 34654586)
37. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, and Jove R (2001) Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 276:45443-45455. (Pubitemid 37406612)
38. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH, Hengstschläger M, et al. (2008) The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29:565-577.
39. Yoshiura S, Ohtsuka T, Takenaka Y, Nagahara H, Yoshikawa K, and Kageyama R (2007) Ultradian oscillations of Stat, Smad, and Hes1 expression in response to serum. Proc Natl Acad Sci U S A 104:11292-11297. (Pubitemid 47175134)
40. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E 3rd, and Zhang Y (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 104:16158-16163.